Want to see WALD full AI Analyst Report?
WALD Stock Chart & Stats
$1.04
-$0.06(-1.90%)
At close: 4:00 PM EST
$1.04
-$0.06(-1.90%)
Day’s Range― - ―
52-Week Range$0.72 - $3.22
Previous CloseN/A
Volume13.42K
Average Volume (3M)145.38K
Market Cap
$215.48M
Enterprise Value$313.40M
Total Cash (Recent Filing)$31.89M
Total Debt (Recent Filing)$149.01M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 06, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.02
Shares Outstanding118,239,890
10 Day Avg. Volume133,325
30 Day Avg. Volume145,381
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.46
Price to Sales (P/S)0.79
P/FCF Ratio-13.20
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue1.15
Enterprise Value/Gross Profit2.53
Enterprise Value/Ebitda-2.05
Forecast
1Y Price Target
$2.50Price Target Upside140.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$297.14M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthManageable leverage and a sizable equity base provide durable financial flexibility. This reduces short‑term refinancing pressure, supports capital allocation for brand investment or M&A, and lowers solvency risk while the company works toward consistent profitability over coming quarters.
Strategic Asset SaleThe planned sale of Obagi Medical is a material structural event: it should materially de‑lever the balance sheet, generate liquidity to fund core brand scaling, and simplify the business. This transaction enhances financial resilience and focuses management on growing Milk Makeup.
Regulatory Approval / Product ValueFDA approval for a regulated injectable creates a higher‑barrier, physician‑led revenue stream and demonstrates R&D and regulatory capability. This structural win boosts long‑term brand value and monetization potential in professional aesthetics, underpinning strategic outcomes like the Obagi sale.
Bears Say
Negative Cash FlowMulti‑year negative operating and free cash flow shows the business is not yet self‑funding and remains reliant on external capital or asset disposals. Persistent cash burn heightens funding risk, constrains reinvestment in marketing and product development, and pressures liquidity over the medium term.
Stalled Revenue And Widening LossesTop‑line stall and larger net losses in 2025 interrupt the path to scale economics. Without resumed revenue growth, fixed costs and marketing investment will continue to pressure margins, making sustainable profitability uncertain and prolonging reliance on balance‑sheet or transactional fixes.
Leadership And Governance DisruptionFounder departures tied to the Obagi transaction, combined with prior accounting restatements and an SEC review, introduce governance and execution risk. Loss of brand stewards and earlier control weaknesses could disrupt continuity, stakeholder trust, and operational execution during the transition period.
Waldencast News
WALD FAQ
What was Waldencast’s price range in the past 12 months?
Waldencast lowest stock price was $0.72 and its highest was $3.22 in the past 12 months.
What is Waldencast’s market cap?
Waldencast’s market cap is $215.48M.
When is Waldencast’s upcoming earnings report date?
Waldencast’s upcoming earnings report date is Aug 06, 2026 which is in 34 days.
How were Waldencast’s earnings last quarter?
Waldencast released its earnings results on May 26, 2026. The company reported -$0.171 earnings per share for the quarter, missing the consensus estimate of -$0.147 by -$0.024.
Is Waldencast overvalued?
According to Wall Street analysts Waldencast’s price is currently Undervalued.
Does Waldencast pay dividends?
Waldencast does not currently pay dividends.
What is Waldencast’s EPS estimate?
Waldencast’s EPS estimate is -0.26.
How many shares outstanding does Waldencast have?
Waldencast has 118,239,890 shares outstanding.
What happened to Waldencast’s price movement after its last earnings report?
Waldencast reported an EPS of -$0.171 in its last earnings report, missing expectations of -$0.147. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Waldencast?
Currently, no hedge funds are holding shares in WALD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Waldencast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (140.38% Upside)
$2.50 (140.38% Upside)
Blogger Sentiment
Bullish
WALD Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.39%
12-Months-Change
Fundamentals
Return on Equity
-47.81%
Trailing 12-Months
Asset Growth
-16.36%
Trailing 12-Months
Company Description
Waldencast
Waldencast plc operates as a specialized skincare enterprise, delivering sophisticated treatments aimed at improving various dermatological conditions. Its product offerings are crafted to minimize the visual impact of early aging, skin damage, uneven pigmentation, acne, and harm from sun exposure. These solutions are predominantly distributed through professional avenues such as dermatologists, plastic surgeons, medical spas, and other skincare professionals. The company's portfolio encompasses Obagi Medical, which provides groundbreaking skincare products designed to alleviate signs of skin aging, treat issues like dark spots, hyperpigmentation, and fine lines, while simultaneously protecting and enhancing skin's overall tone and texture. Additionally, its Obagi Clinical line features products specifically developed to stave off the initial indicators of skin aging. Founded in 1988, Waldencast plc is based in White Plains, New York.
WALD Stock 12 Month Forecast
Average Price Target
$2.50
▲(140.38% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.98% Mutual Funds
14.10% Other Institutional Investors
84.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---